ATPS-64: PRECLINICAL STUDIES USING NATIVIS VOYAGER RFE SYSTEM, A NOVEL NON-INVASIVE, LOW ENERGY, NON-THERMAL, NON-IONIZING RADIOFREQUENCY ENERGY (RFE) DEVICE IN GLIOBLASTOMA MOUSE MODELS

BACKGROUND: Cancer treatment using radiofrequency energy (RFE) devices have been used in the past and have recently shown benefit in clinical trials of glioblastoma. Here we report a proof-of-concept application using the Nativis Voyager RFE System, which provides specific, low energy, non-invasive, non-thermal and non-ionizing oscillating electromagnetic signals. These signals inhibit in vitro glioblastoma tumor cell proliferation via an anti-mitotic effect. METHODS: We tested the ability of Voyager RFE System signals to inhibit tumor growth in both immunocompromised and immunocompetent mouse models. The immunocompetent model study, using white noise signal compared to control showed no difference in growth in the two groups. After establishing this, in the immunocompromised model, we implanted human U87 cells subcutaneously into 6-8 week old nude mice. In the immunocompetent model, we implanted mouse GL261 cells subcutaneously into 6-8 week old C57/BL6 mice. Voyager RFE signal was started ∼10-14 days after cells were implanted, when there were small, measurable tumors. There were two treatment groups (N = 10 tumors each group). The control group was housed in a separate room and was not treated with any RFE signal. The treatment group was treated with Voyager RFE signal 24 hours daily. Voyager RFE signal was applied using a rectangular 40mG coil placed under the cage. Tumors were measured ∼weekly. RESULTS: In the immunocompromised U87 model, tumor growth was significantly delayed in Voyager RFE signal group compared to control group (at day 39; p < 0.0001). Moreover, in the immunocompetent GL261 model, tumor growth was significantly delayed in Voyager RFE signal group compared to control group (at day 28; p < 0.0001). CONCLUSIONS: We show that Nativis Voyager RFE System signal delays glioblastoma tumor growth in SQ immunocompromised and immunocompetent mouse models.